LLY vs MRK stock comparison
ELI LILLY & Co vs. Merck & Co. · data as of November 13, 2026
ELI LILLY & Co (LLY) has a market value of about $1.36T, Merck & Co. (MRK) about $364.3B. Over their latest twelve months ELI LILLY & Co had revenue of $86.5B and Merck & Co. $67.4B.
On our five checks ELI LILLY & Co scores higher: 3.4 out of 5 (good) against 2.8 (average).
By area, the stronger company is ELI LILLY & Co on future growth; ELI LILLY & Co on financial health; Merck & Co. on shareholder returns.
ELI LILLY & Co is cheaper on earnings (P/E 46.9 vs. 150.8).
ELI LILLY & Co leads on 13 of the compared lines and Merck & Co. on 10.
Side by side
| LLY | MRK | |
|---|---|---|
| Size and price | ||
| Market cap | $1.36T | $364.3B |
| Share price | $1,443.50 | $147.76 |
| Score | ||
| Overall score (of 5) | 3.4 | 2.8 |
| Value | 0 | 0 |
| Future growth | 5 | 2 |
| Track record | 5 | 5 |
| Financial health | 3 | 2 |
| Shareholder returns | 4 | 5 |
| Valuation | ||
| P/E (TTM) | 46.9 | 150.8 |
| Forward P/E | 30.4 | 17.6 |
| Price / free cash flow | 69.1 | 24.7 |
| Price / sales | 15.7 | 5.4 |
| EV / EBITDA | 37.1 | 32.5 |
| PEG | 1.70 | 7.10 |
| DCF value vs. price | −37% | −31% |
| Business | ||
| Revenue | $86.5B | $67.4B |
| Net income | $27.6B | $2.5B |
| Free cash flow | $19.7B | $14.7B |
| Net margin | 31.9% | 3.6% |
| Gross margin (5-yr avg.) | 78.9% | 73.4% |
| ROIC (5-yr avg.) | 22.9% | 16.3% |
| Growth | ||
| Revenue growth (1 yr) | 44.7% | 1.3% |
| Revenue growth (5 yrs, per year) | 21.6% | 9.4% |
| EPS growth (5 yrs, per year) | 27.6% | 21.2% |
| Balance sheet and payouts | ||
| Net cash (cash minus debt) | -$44.6B | -$44.1B |
| Dividend yield | 0.48% | 2.30% |
| Shareholder yield | 0.8% | 3.7% |
| Analysts | ||
| Upside to average target | +1% | +9% |
| Consensus rating | Buy | Buy |
Highlighted = the better figure on that line. Revenue, net income and free cash flow: LLY TTM to September 30, 2026, MRK TTM to September 30, 2026. Not investment advice.
Frequently asked questions
Which is the better stock, ELI LILLY & Co or Merck & Co.?
We do not give buy or sell advice. On our five checks (value, growth, track record, financial health and shareholder returns) ELI LILLY & Co scores 3.4 out of 5 and Merck & Co. 2.8; the table shows where each one is stronger.
Is ELI LILLY & Co cheaper than Merck & Co.?
On trailing earnings, ELI LILLY & Co trades at a P/E of 46.9 and Merck & Co. at 150.8, so ELI LILLY & Co is cheaper by this measure. A lower P/E can also reflect slower expected growth.
Which grows faster, ELI LILLY & Co or Merck & Co.?
Over five years ELI LILLY & Co grew revenue about 21.6% a year and Merck & Co. about 9.4% a year.
Which pays a higher dividend?
ELI LILLY & Co yields 0.48% and Merck & Co. 2.30%.
Full ELI LILLY & Co analysis → Full Merck & Co. analysis →
More comparisons
Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.